IN BRIEF
- Jaguar is supplying XF Sportbrakes to Leukaemia & Lymphoma Research for London to Paris Bike Ride
- London to Paris Bike Ride began on Thursday 6th June and will finish Monday 10th June 2013
- Four Jaguar Land Rover employees to take part in the challenging cycling event, raising funds for Leukaemia & Lymphoma Research
IN DETAIL
Jaguar is strengthening its presence in cycling by supporting Leukaemia & Lymphoma Research in the London | Paris: Be Unstoppable bike ride. XF Sportbrakes, wearing new livery designed specifically for this event, are being be deployed by the charity throughout the 250‑mile event route.
Jaguar is a partner of Team Sky and the versatile XF Sportbrake is supplied as a support vehicle to the current Tour de France Champions for all competitions in 2013. The cars will accompany riders on the London to Paris bike ride for the duration of the journey, carrying essential refreshments and all spare mechanical components for the bikes.
Four Jaguar Land Rover employees are taking part in the ride, joining the 170‑strong group who will take in the picturesque and undulating roads of Kent and northern France on their way to Paris. On Monday the riders arrive in the city, where they will pass by the famous Arc de Triomphe and the Etoile with a police escort, before finishing under the Eiffel Tower.
David Steele, Jaguar Global Experiential Director said:"We have a developed a great understanding of the needs of cyclists in top‑level competition, and know that the versatility of the XF Sportbrake makes it the ideal vehicle to support both the organisers and participants on this gruelling event."
Dan Solley, Head of Sports Fundraising at Leukaemia & Lymphoma Researchsaid:"We are constantly inspired by the stories of those taking part in events for the charity and the dedication of our supporters. Every penny raised for Leukaemia & Lymphoma Research will help us in our mission to beat blood cancer, stop people from dying, and make patients' lives better. We wish the best of luck to everyone taking part in the London to Paris ride."
‑ ENDS ‑
Editors' notes
A selection of images is attached.
For further Jaguar XF Sportbrake images, see www.media.jaguar.com.
Jaguar XF Sportbrake product highlights
- The XF Sportbrake is the most versatile derivative of the Jaguar XF
- It represents a compelling combination of elegance and capability ‑ both practical and dynamic
- It extends Jaguar's design leadership in a new direction to create a desirable, premium estate
- Remote‑fold levers drop the 60:40 split rear seats (with integral ski‑hatch) to create up to 1675 litres of load‑space
- A full five‑seater with an additional 48mm of rear headroom
- New rear air suspension allows for self‑levelling while load carrying with no dynamic penalty
- Jaguar's Adaptive Dynamics System ‑ which continuously monitors the suspension and can adjust damping rates accordingly up to 500 times a second ‑ is available on all XF Sportbrake derivatives
- Tailgate features 'soft‑close' as standard, and can be specified with fully powered open/close functionality
- Acclaimed premium‑quality interior materials used in the cabin are also a feature of the load‑space
- Available with both Aero and Black styling packs from launch for additional on‑the‑road presence
- Driven by Jaguar's refined, powerful and efficient range of four‑ and six‑cylinder turbo‑diesel engines
- Matches the XF saloon for both aerodynamics, torsional stiffness and dynamic handling ability
- A range of accessories ‑ both internally mounted by floor rails and externally by roof rails ‑ extends the versatility of the XF Sportbrake still further
AboutLeukaemia & Lymphoma Research
- Leukaemia & Lymphoma Research is dedicated to saving the lives of blood cancer patients through the promotion and assistance of research into causes, diagnosis and treatment. We are committed to advancing the interests of patients and increasing public understanding of blood cancers.
- Around 30,000 people of all ages, from children to adults, are diagnosed with blood cancers such as leukaemia, lymphoma and myeloma every year in the UK.
- Leukaemia & Lymphoma Research receives no government funding and relies entirely on voluntary support. In the next five years it aims to raise £120 million to continue its lifesaving research. Further information, including patient information booklets, is available from beatingbloodcancers.org.uk or on 020 7504 2200.